Developing an approach for evaluating the cardiotoxic potential of botanicals
Frontiers in Toxicology · 30.10.2025 · 7
DOI: 10.3389/ftox.2025.1646044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Toxicology, online erschienen am 30.10.2025. Verfasst von Julie Krzykwa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Health and Environmental Sciences Institute, Washington, DC, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Botanicals (e.g., extracts derived from plants, algae, or fungi) are increasingly utilized by consumers with the hope of enhancing their health, managing symptoms, or preventing ailments; however, these products have often had limited pre-market toxicity testing. Traditional toxicity testing (e.g., rodent testing) is complicated by the nature of botanicals as complex mixtures and the potential for lot-to-lot variability in chemical constituents. Cardiotoxicity is a key area of concern, as adverse effects on the cardiovascular system can have severe consequences, and although not commonly reported, there have been reports of adverse cardiac events. New approach methodologies (NAMs) offer human-relevant, efficient, innovative, and cost-effective solutions for evaluating the cardiotoxicity of botanicals. The Botanical Safety Consortium (BSC) was established to focus on identifying suitable NAMs to screen for potential toxicities associated with these widely used products. This manuscript outlines the BSC Cardiotoxicity Working Group’s approach for evaluating NAMs for assessing the potential cardiotoxicity of botanicals. These NAMs leverage in vitro models, such as human-induced pluripotent stem cell-derived cardiomyocytes, and techniques like microelectrode arrays, voltage and calcium optical mapping, contractile force measurement, and mitochondrial function assays to evaluate botanical-induced effects on the cardiovascular system. Using well-characterized botanical extracts as case studies, the BSC aims to refine a toolkit for high-throughput and human-relevant cardiotoxicity screening. This foundational work supports the broader goal of improving botanical safety assessment practices and advancing the application of NAMs in regulatory toxicology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health and Environmental Sciences Institute, Washington, DC, United States.
- L'Oréal Research and Innovation, Clark, NJ, United States.
- Frankel Cardiovascular Center Cell Regeneration Core/Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, United States.
- innoVitro GmbH, Juelich, Germany.
- Consultant, Beaufort, SC, United States.
- Stanford Cardiovascular Institute, Stanford University, Stanford, CA, United States.
Förderung
- Intramural NIH HHS
Zitieren
APA
Krzykwa, J., Chaudhari, H. S., Monteiro Da Rocha, A., Gossmann, M., Hoffmann, P., Khokhar, Y., Meyer, N., Park, J. K., Sprando, R., Vaidyanathan, R., Westerink, R. H. S., Wu, J. C., Yourick, J., Zhao, S. R., & Mitchell, C. A. (2025). Developing an approach for evaluating the cardiotoxic potential of botanicals. Frontiers in Toxicology, 7. https://doi.org/10.3389/ftox.2025.1646044
Vancouver
Krzykwa J, Chaudhari HS, Monteiro Da Rocha A, Gossmann M, Hoffmann P, Khokhar Y, et al. Developing an approach for evaluating the cardiotoxic potential of botanicals. Frontiers in Toxicology. 2025;7. doi:10.3389/ftox.2025.1646044
BibTeX
@article{Krzykwa2025,
author = {Krzykwa, Julie and Chaudhari, Hemantkumar S and Monteiro Da Rocha, Andre and Gossmann, Matthias and Hoffmann, Peter and Khokhar, Yaser and Meyer, Nathan and Park, Jin-Young K and Sprando, Robert and Vaidyanathan, Ravi and Westerink, Remco H S and Wu, Joseph C and Yourick, Jeffrey and Zhao, Shane R and Mitchell, Constance A},
title = {Developing an approach for evaluating the cardiotoxic potential of botanicals},
journal = {Frontiers in Toxicology},
year = {2025},
volume = {7},
doi = {10.3389/ftox.2025.1646044}
}
EUVIMED